Ipamorelin

Ipamorelin is a selective growth hormone secretagogue developed to stimulate GH release without significantly affecting other pituitary hormones. It has gained promise in the research setting for its targeted action and relatively favorable side effect profile.

Areas studied include: Age-related GH decline; Muscle recovery; Fat metabolism; Sleep quality.

Ipamorelin binds to ghrelin receptors in the pituitary gland (a gland found in the brain), triggering GH release while minimizing effects on cortisol and prolactin. This selectivity makes it attractive for research into metabolic health and recovery.

Ipamorelin is generally well tolerated in research studies, with fewer reports of water retention or appetite stimulation compared to older GH secretagogues. Long-term human data remains limited.

One commonly referenced research protocol is: Week 1: 100 mcg (0.1 mg) daily; Week 2: 100 mcg (0.1 mg) twice daily, for 200 mcg (0.2 mg) total every day; Week 3 and beyond: 150 mcg (0.15 mg) twice daily, for 300 mcg (0.3 mg) total every day. Shown for education only; a licensed clinician should set any actual dose. See the dosing table.

Wipe the vial tops with alcohol, add bacteriostatic water slowly so it runs down the inside of the glass, then roll the vial gently until the powder dissolves; don’t shake it. See the step-by-step guide with diagrams for the pen and syringe methods.

There is no single correct amount. We recommend 2.1 mL: about 0.1 mL is lost during transfer, leaving roughly 2.0 mL of usable solution. You can add more or less (most peptide vials hold up to 3 mL); just enter the amount in the dose calculator. See the step-by-step mixing guide.

No. Ipamorelin is not FDA-approved in the US (status as of October 2026).